A Compassionate Use/Expanded Access Protocol Using 131I-MIBG Therapy for Patients With Refractory Neuroblastoma and Metastatic Pheochromocytoma

Trial Profile

A Compassionate Use/Expanded Access Protocol Using 131I-MIBG Therapy for Patients With Refractory Neuroblastoma and Metastatic Pheochromocytoma

Suspended
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 13 Jan 2017

At a glance

  • Drugs Iobenguane (Primary)
  • Indications Neuroblastoma
  • Focus Adverse reactions; Expanded access; Therapeutic Use
  • Most Recent Events

    • 13 Jan 2017 Trial focus is assumed since, primary endpoints were not mentioned
    • 12 Jan 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top